Luca Gianni

12PUBLICATIONS
87CO-AUTHORS
Predictive and prognostic markersShip and platform structures (incl. maritime hydrodynamics)Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsEnvironmental epidemiology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Sep 23, 2024
The Immune-Related 27-Gene Signature DetermaIO Predicts Response to Neoadjuvant Atezolizumab plus Chemotherapy in Triple-Negative Breast Cancer.

Matteo Dugo, Chiun-Sheng Huang, Daniel Egle

|Feb 29, 2024
Final Results From the Randomized Phase III ASCENT Clinical Trial in Metastatic Triple-Negative Breast Cancer and Association of Outcomes by Human Epidermal Growth Factor Receptor 2 and Trophoblast Cell Surface Antigen 2 Expression.

Aditya Bardia, Hope S Rugo, Sara M Tolaney

|Apr 19, 2023
Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer.

Marion T van Mackelenbergh, Sibylle Loibl, Michael Untch

|Mar 28, 2023
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 Therapy.

Pierre Squifflet, Everardo D Saad, Sibylle Loibl

|Aug 29, 2022
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer.

Hope S Rugo, Sara M Tolaney, Delphine Loirat

|Jun 10, 2022
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis.

Lisa A Carey, Delphine Loirat, Kevin Punie

Pageof 2

Frequent Collaborators

6 joint publications

Javier Cortés

4 joint publications

Giampaolo Bianchini

4 joint publications

Sara A Hurvitz

4 joint publications

Kevin Punie